XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.3
Unaudited Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Total
Common stock
Additional paid-in capital
Accumulated other comprehensive (loss) income
Accumulated deficit
Noncontrolling interests
Beginning balance (in shares) at Dec. 31, 2022 8,700,885          
Beginning balance at Dec. 31, 2022 $ 107,808          
Convertible preferred stock            
Conversion of convertible preferred stock and non-controlling interests to common stock (in shares) (8,700,885)          
Conversion of convertible preferred stock and non-controlling interests to common stock $ (107,808)          
Ending balance (in shares) at Mar. 31, 2023 0          
Ending balance at Mar. 31, 2023 $ 0          
Beginning balance (in shares) at Dec. 31, 2022   2,217,737        
Beginning balance at Dec. 31, 2022 (142,670) $ 2 $ 1,197 $ (41) $ (158,223) $ 14,395
Stockholders’ Equity (Deficit)            
Stock-based compensation 265 $ 0 265      
Unrealized gain on marketable securities 177     177    
Issuance of common stock for cash in pre-closing financing (in shares)   3,730,608        
Issuance of common stock for cash in pre-closing financing 30,640 $ 4 30,636      
Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability (in shares)   5,059,338        
Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability 42,447 $ 5 42,442      
Issuance of common stock to Sesen Bio shareholders in reverse capitalization (in shares)   10,374,272        
Issuance of common stock to Sesen Bio shareholders in reverse capitalization 72,044 $ 10 72,034      
Conversion of convertible preferred stock and non-controlling interests to common stock (in shares)   18,872,711        
Conversion of convertible preferred stock and non-controlling interests to common stock 107,809 $ 19 122,185     (14,395)
Net loss (24,642)       (24,642)  
Ending balance (in shares) at Mar. 31, 2023   40,254,666        
Ending balance at Mar. 31, 2023 $ 86,070 $ 40 268,759 136 (182,865) 0
Beginning balance (in shares) at Dec. 31, 2022 8,700,885          
Beginning balance at Dec. 31, 2022 $ 107,808          
Ending balance (in shares) at Sep. 30, 2023 0          
Ending balance at Sep. 30, 2023 $ 0          
Beginning balance (in shares) at Dec. 31, 2022   2,217,737        
Beginning balance at Dec. 31, 2022 (142,670) $ 2 1,197 (41) (158,223) 14,395
Stockholders’ Equity (Deficit)            
Unrealized gain on marketable securities 414          
Net loss (65,921)          
Ending balance (in shares) at Sep. 30, 2023   40,304,436        
Ending balance at Sep. 30, 2023 $ 46,298 $ 40 270,029 373 (224,144) 0
Beginning balance (in shares) at Mar. 31, 2023 0          
Beginning balance at Mar. 31, 2023 $ 0          
Ending balance (in shares) at Jun. 30, 2023 0          
Ending balance at Jun. 30, 2023 $ 0          
Beginning balance (in shares) at Mar. 31, 2023   40,254,666        
Beginning balance at Mar. 31, 2023 86,070 $ 40 268,759 136 (182,865) 0
Stockholders’ Equity (Deficit)            
Exercise of stock options (in shares)   14,910        
Exercise of stock options 52   52      
Stock-based compensation 330 $ 0 330      
Unrealized gain on marketable securities 129     129    
Net loss (19,876)       (19,876)  
Ending balance (in shares) at Jun. 30, 2023   40,269,576        
Ending balance at Jun. 30, 2023 $ 66,705 $ 40 269,141 265 (202,741) 0
Ending balance (in shares) at Sep. 30, 2023 0          
Ending balance at Sep. 30, 2023 $ 0          
Stockholders’ Equity (Deficit)            
Exercise of stock options (in shares)   34,860        
Exercise of stock options 40   40      
Stock-based compensation 848   848      
Unrealized gain on marketable securities 108     108    
Net loss (21,403)       (21,403)  
Ending balance (in shares) at Sep. 30, 2023   40,304,436        
Ending balance at Sep. 30, 2023 $ 46,298 $ 40 270,029 373 (224,144) 0
Beginning balance (in shares) at Dec. 31, 2023 0          
Beginning balance at Dec. 31, 2023 $ 0          
Ending balance (in shares) at Mar. 31, 2024 0          
Ending balance at Mar. 31, 2024 $ 0          
Beginning balance (in shares) at Dec. 31, 2023   40,609,915        
Beginning balance at Dec. 31, 2023 26,532 $ 40 271,594 0 (245,102) 0
Stockholders’ Equity (Deficit)            
Exercise of stock options (in shares)   1,579        
Exercise of stock options 2   2      
Stock-based compensation 1,057 $ 0 1,057      
Sale of common stock under Open Market Sales Agreement, net of issuance costs (in shares)   931,250        
Sale of common stock under Open Market Sales Agreement, net of issuance costs 2,282 $ 1 2,281      
Net loss (18,978)       (18,978)  
Ending balance (in shares) at Mar. 31, 2024   41,542,744        
Ending balance at Mar. 31, 2024 $ 10,895 $ 41 274,934 0 (264,080) 0
Beginning balance (in shares) at Dec. 31, 2023 0          
Beginning balance at Dec. 31, 2023 $ 0          
Ending balance (in shares) at Sep. 30, 2024 0          
Ending balance at Sep. 30, 2024 $ 0          
Beginning balance (in shares) at Dec. 31, 2023   40,609,915        
Beginning balance at Dec. 31, 2023 $ 26,532 $ 40 271,594 0 (245,102) 0
Stockholders’ Equity (Deficit)            
Exercise of stock options (in shares) 3,810          
Unrealized gain on marketable securities $ 0          
Net loss (42,842)          
Ending balance (in shares) at Sep. 30, 2024   41,750,109        
Ending balance at Sep. 30, 2024 $ (11,126) $ 41 276,777 0 (287,944) 0
Beginning balance (in shares) at Mar. 31, 2024 0          
Beginning balance at Mar. 31, 2024 $ 0          
Ending balance (in shares) at Jun. 30, 2024 0          
Ending balance at Jun. 30, 2024 $ 0          
Beginning balance (in shares) at Mar. 31, 2024   41,542,744        
Beginning balance at Mar. 31, 2024 10,895 $ 41 274,934 0 (264,080) 0
Stockholders’ Equity (Deficit)            
Exercise of stock options (in shares)   2,231        
Exercise of stock options 2   2      
Stock-based compensation 625 $ 0 625      
Net loss (11,162)       (11,162)  
Ending balance (in shares) at Jun. 30, 2024   41,544,975        
Ending balance at Jun. 30, 2024 $ 360 $ 41 275,561 0 (275,242) 0
Ending balance (in shares) at Sep. 30, 2024 0          
Ending balance at Sep. 30, 2024 $ 0          
Stockholders’ Equity (Deficit)            
Stock-based compensation 1,115   1,115      
Unrealized gain on marketable securities 0          
Sale of common stock under Open Market Sales Agreement, net of issuance costs (in shares)   205,134        
Sale of common stock under Open Market Sales Agreement, net of issuance costs 101   101      
Net loss (12,702)       (12,702)  
Ending balance (in shares) at Sep. 30, 2024   41,750,109        
Ending balance at Sep. 30, 2024 $ (11,126) $ 41 $ 276,777 $ 0 $ (287,944) $ 0